EFX vs FDMT · P/E 54, rev $5.68B vs rev $37.0K
Equifax Inc (EFX) versus 4D Molecular Therapeutics Inc (FDMT) — a side-by-side from cached financials, not a winner call.
Equifax Inc (EFX) is a consulting services company listed on US.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
EFX currently screens at market cap $33.00B and trailing P/E 54.0. FDMT currently screens at market cap $518.1M.
Not investment advice. Open the EFX and FDMT stock pages for the full models.
Not investment advice.